[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-371629-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-371629-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","prognostic-value-of-the-stan-score-in-elderly-small-cell-lung-cancer-research-article-overview","Prognostic value of the StAN score in elderly small cell lung cancer - Research article overview","","Study examines how the StAN score predicts survival in elderly patients with small cell lung cancer. A retrospective cohort of 117 individuals aged 65+ with diagnoses from 2007–2023 was analyzed using clinical factors including stage (extensive vs limited), hemoglobin status (normal vs low), and prognostic nutritional index categories (\u003C median vs ≥ median). Overall survival and progression-free survival were estimated with Kaplan–Meier and Cox models, showing poorer outcomes for low-PNI and StAN high-risk groups. Reported Harrell’s C indices indicate reliable prognostic performance and clinical utility.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/prognostic-value-of-the-stan-score-in-elderly-small-cell-lung-cancer-research-article-overview/371629/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/prognostic-value-of-the-stan-score-in-elderly-small-cell-lung-cancer-research-article-overview/371629.png","ImageObject",300,407,{"name":42,"@type":43},"Putri","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-28","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What clinical components are included in the StAN score?","Question",{"text":63,"@type":64},"The StAN score combines disease stage (extensive vs limited), hemoglobin level (normal vs low), and prognostic nutritional index (PNI) divided by the median cutoff.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was overall survival (OS) and progression-free survival (PFS) evaluated?",{"text":68,"@type":64},"OS and PFS were assessed using Kaplan–Meier estimates and compared using Cox proportional hazards models, with reported hazard ratios and p-values.",{"name":70,"@type":61,"acceptedAnswer":71},"What do the results show for low PNI and high StAN risk groups?",{"text":72,"@type":64},"Low PNI was associated with shorter OS and PFS. Patients classified as high risk by the StAN score also had significantly shorter OS and PFS, indicating stronger prognostic discrimination.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},371629,1790735839,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":108,"slug":109},7,40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},8,"Research & Report",30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":107,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":116,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145},962085571259,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nPrognostic value of the StAN score in elderly small cell lung cancer  \nFerideYılmaz1􀀍, SerkanYaşar2, Ömer Denizhan Tatar3, Hasan ÇağrıYıldırım4, DenizcanGüven5, BurakYasin Aktaş5, Hakan Taban6, Zafer Arık5 & Mustafa Erman5  \nLung cancer, the leading cause of cancer-related mortality, includes small-cell lung cancer (SCLC), which accounts for 15% of cases. The median age of lung cancer diagnosis is 71, highlighting the need for accessible prognostic tools in elderly patients. The prognostic nutritional index (PNI) has shown promise in predicting survival in various cancers. This study evaluates the performance of a PNI-based novel scoring system in elderly SCLC patients. We analyzed 117 patients aged ≥ 65 diagnosed with SCLC between 2007 and 2023. Data on age, Eastern Cooperative Oncology Group Scale (ECOG) performance status, hemoglobin levels, disease stage, and PNI were collected. The StAN score, incorporating stage ([extensive vs. limited](extensive vs. limited)), hemoglobin (normal vs. low), and PNI (\u003C median vs. ≥ median), was derived from multivariate analyses. Patients were classified into low-and high-risk categories. Kaplan-Meier and Cox models assessed overall survival (OS) and progression-free survival (PFS). The median age was 71 years, with 89.7% male patients. Median follow-up was 12.4 months. Patients with low PNI had shorter OS (7.6 vs. 18.2 months, p \u003C 0.001) and PFS (5.4 vs. 10.3 months, p \u003C 0.001). High-risk patients, based on the StAN score, had shorter OS (7.8 vs. 18.5 months, HR 2.38, p \u003C 0.001) and PFS (5.4 vs.  \n10.3 months, HR 2.29, p \u003C 0.001). Harrell’s C indices for predicting OS and PFS were 0.72 and 0.73, respectively. In conclusion, the StAN score is a reliable prognostic tool for elderly SCLC patients and may help stratify patients and improve treatment strategies.  \nKeywords Small-cell lung cancer, Nutrition, Elderly patients, Prognosis, Survival, Prognostic model, Geriatric oncology  \nSmall-cell lung cancer (SCLC) is an aggressive malignancy and represents approximately 15% of all lung cancers. It is characterized by aggressive growth, early metastatic spread, and an overall poor prognosis, with a five-year survival rate of less than 10%, especially among elderly patients1,2. According to Surveillance, Epidemiology, and End Results (SEER) data, the median age at lung cancer diagnosis is 71 years3which has led to accessible and easily applicable prognostic tools to alleviate the disease burden in the elderly population.  \nElderly SCLC patients often face unique challenges due to their comorbidities, diminished physiologic reserves, and greater susceptibility to treatment-related complications. Despite advances in systemic therapies, including chemotherapy and the introduction of immunotherapy, survival outcomes for patients with extensivestage SCLC (ES-SCLC) remain limited4,5. Specific prognostic tools that include routinely used clinical parameters to optimize treatment strategies in this patient group are of clinical importance6,7. The use of prognostic factors allows the easy identification of different subgroups in the evaluation of response to treatment and thus the determination of innovative and personalized treatment methods that can affect the survival of patients4,8.  \nBoth inflammation and nutritional status are known to influence cancer progression and patient survival. The prognostic nutritional index (PNI), which is calculated from serum albumin levels and total lymphocyte counts, has been widely studied as a biomarker reflecting both the immune and nutritional conditions of patients2. It has shown prognostic value in various cancers, including SCLC, where lower PNI values have been associated with poorer overall survival (OS)2,8. A study has shown that the advanced lung cancer inflammation index (ALI) performs well in predicting the overall prognosis of lung cancer patients and most subgroups. In anoth","cbCaihRQ0ZD7Xlf5","https://ap.wps.com/l/cbCaihRQ0ZD7Xlf5","pdf",1714343,"English","# Materials and methods\n## Patient selection\n## Baseline data collection","[{\"question\":\"What clinical components are included in the StAN score?\",\"answer\":\"The StAN score combines disease stage (extensive vs limited), hemoglobin level (normal vs low), and prognostic nutritional index (PNI) divided by the median cutoff.\"},{\"question\":\"How was overall survival (OS) and progression-free survival (PFS) evaluated?\",\"answer\":\"OS and PFS were assessed using Kaplan–Meier estimates and compared using Cox proportional hazards models, with reported hazard ratios and p-values.\"},{\"question\":\"What do the results show for low PNI and high StAN risk groups?\",\"answer\":\"Low PNI was associated with shorter OS and PFS. Patients classified as high risk by the StAN score also had significantly shorter OS and PFS, indicating stronger prognostic discrimination.\"}]","Prognostic value of the StAN score in elderly small cell lung cancer - Research article overview | PDF",1790192489,23]